Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 19/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.64 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.64 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118842 | 0.87 | SLC22A12 (0.68) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL95728 | 0.87 | SLC22A12 (0.68) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL3720283 | 0.83 | SLC22A12 (0.62) | SLC22A12MEN1ALDH1A1KMT2A | |
| SCHEMBL15480544 | 0.81 | SLC22A12 (0.60) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL7627388 | 0.80 | KEAP1 (0.67) | MEN1ALDH1A1KMT2A | |
| SCHEMBL15486381 | 0.80 | SLC22A12 (0.77) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL3555598 | 0.80 | PKLR (0.58) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL17698979 | 0.79 | SLC22A12 (0.60) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL29541246 | 0.79 | SLC22A12 (0.69) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL17559542 | 0.79 | SLC22A12 (1.00) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| WO-2008142376-A1 | BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | INHIBOX LTD. (GB) | 2008-11-27 | — | — | WO | disclosed |
| CN-1349381-A | Sulfonamide derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | TNF, CS, COASY | SLC22A12 3168/4885CYP2C9 2118/4885SLC22A6 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.